Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 11, 1996, Pages 3930-3937

  Moretti, Roberta M ^a   Montagnani Marelli, Marina ^a   Dondi, Donatella ^a   Poletti, Angelo ^a   Martini, Luciano ^a   Motta, Marcella ^a   Limonta, Patrizia ^a  

^a Center for Endocrinological Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN AGONIST; GOSERELIN;

ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

CELL DIVISION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; GENES, FOS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TYROSINE;

EID: 10344248844     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.11.3930     Document Type: Article

References (43)

1. Motta M, Serio M, eds. 1988 Hormonal therapy of prostatic diseases: basic and clinical aspects. Amsterdam: Medicom Europe.
2. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. 1992 Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab. 75:207-212.
3. Dondi D, Limonta P, Moretti RM, Montagnani Marelli M, Garattini E, Motta M. 1994 Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory loop. Cancer Res. 54:4091-4095.
4. Connolly JM, Rose DP. 1990 Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human cancer cell line. Prostate. 16:209-218.
5. Connolly JM, Rose DP. 1991 Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate. 19:173-180.
6. Ware JL. 1993 Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev. 12:287-301.
7. Limonta P, Moretti RM, Dondi D, Montagnani Marelli M, Motta M. 1994 The EGF/TGFα system as an autocrine growth stimulatory loop in LNCaP cells. Endocr Rel Cancer. 3:5-13.
8. Helle SI, Lonning PE. 1995 Insulin-like growth factors in breast and prostatic cancer. Endocr Rel Cancer. 2:153-169.
9. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. 1983 Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA. 80:1337-1341.
10. Gill GN, Kawamoto T, Cochet C, et al. 1984 Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem. 259:7755-7760.
11. Mitchell RL, Zokas L, Schreiber RD, Verma IM. 1985 Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell. 40:209-217.
12. Persico MG, Viglietto G, Martini G, et al. 1986 Isolation of human glucose6-phosphate dehydrogenase (G6PDH) DNA clones: primary structure of the protein and unusual 5′ non-coding region. Nucleic Acids Res. 14:2511-2516.
13. Horoszewicz JS, Leong SS, Kawinski E, et al. 1983 LNCaP model of human prostatic carcinoma. Cancer Res. 43:1809-1818.
14. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. 1978 Isolation of a human prostatic carcinoma cell line (DU 145). Int J Cancer. 21:274-281.
15. Culig Z, Klocher H, Eberle J, et al. 1993 DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate. 22:11-22.
16. Schuurmans ALG, Bolt J, Mulder E. 1988 Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate. 12:55-63.
17. Izumi H, Ono M, Ushiro S, Kohno K, Kung H-F, Kuwano M. 1994 Cross talk of tumor necrosis factor-α and epidermal growth factor in human microvascular endothelial cells. Exp Cell Res. 214:654-662.
18. Laemmli UK. 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-685.
19. Ono M, Okamura K, Nakayama Y, et al. 1992 Induction of human microvascular endothelial tubular morphogenesis by human keratinocytes: involvement of transforming growth factor-α. Biochem Biophys Res Commun. 189:601-609.
20. Chirgwin J, Aeyble A, McDonald R, Rutter W. 1979 Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:5294-5299.
21. Rigby PWJ, Dieckmann C, Rhodes C, Berg P. 1977 Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol. 113:237-251.
22. Limonta P, Ladizhenskaya A, Gunsalus GL, Bardin CW, Thau RB. 1986 Regulation of pituitary gonadotropin-releasing hormone receptors by androgens in the male rabbit. Endocrinology. 118:340-347.
23. Bradford MM. 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248-254.
24. Dunnett W. 1955 A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 50:1096-1121.
25. Munson PJ, Rodbard D. 1980 LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 107:220-239.
26. MacDonald A, Habib FK. 1992 Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer. 65:177-182.
27. Carpenter G, Cohen S. 1990 Epidermal growth factor. J Biol Chem. 265:7709-7712.
28. Ullrich A, Schlessinger J. 1990 Signal transduction by receptors with tyrosine kinase activity. Cell. 61:203-212.
29. Herschman HR. 1991 Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem. 60:281-319.
30. Hauguel-DeMouzon S, Csermely P, Zoppini G, Kahn CR. 1992 Quantitative dissociation between EGF effects on c-myc and c-fos gene expression, DNA synthesis, and epidermal growth factor receptor tyrosine kinase activity. J Cell Physiol. 150:180-187.
31. Fantl WJ, Johnson DE, Williams LT. 1993 Signalling by receptor tyrosine kinases. Annu Rev Biochem. 62:453-481.
32. Mueller H, Loop P, Liu R, Wosikowski K, Kueng W, Eppenberger U. 1994 Differential signal transduction of epidermal-growth-factor receptors in hormone-dependent and hormone-independent human breast cancer cells. Eur J Biochem. 221:631-637.
33. Fekete M, Redding TW, Comaru-Schally AM, et al. 1989 Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate. 14:191-208.
34. Pinski J, Reile H, Halmos G, Groot K, Schally AV. 1994 Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer. 59:51-55.
35. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. 1994 Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA. 91:7090-7094.
36. Shirahige Y, Cook CB, Pinski J, Halmos G, Nair R, Schally AV. 1994 Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol. 5:1031-1035.
37. Szende B, Srkalovic G, Groot K, Lapis K, Schally AV. 1990 Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J Natl Cancer Inst. 82:13-17.
38. Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally AV. 1993 Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing hormone-releasing hormone in MXT mouse mammary carcinoma. J Cancer Res Clin Oncol. 119:273-278.
39. Lee MT, Liebow C, Kamer AR, Schally AV. 1991 Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA. 88:1656-1660.
40. Hershkovitz E, Marbach M, Bosin E, et al. 1993 Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab. 77:963-968.
41. Berns EMJJ, De Boer W, Mulder E. 1983 Androgen dependent growth regulation and the release of specific proteins by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate. 9:247-259.
42. Henttu P, Liao S, Vihko P. 1992 Androgens up-regulate the human prostatespecific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology. 130:766-772.
43. Connolly JM, Rose DP. 1994 Regulation of DU 145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate. 24:167-175.